WOBURN, Mass.–(BUSINESS WIRE)–ReForm
Biologics, a privately-held pharmaceutical technology company
developing innovative biologic formulations to improve drug delivery and
manufacturing, today announced a collaboration with Astellas Pharma Inc.
(TSE: 4503,”Astellas”) to reduce the viscosity of an Astellas
clinical-stage biological pipeline program. Reform’s technology platform
transforms the formulation of biotherapeutics in order to enable
alternative dosing, improve manufacturing efficiency and extend product
life-cycles.

Under the terms of the agreement, Astellas will provide funding for the
collaboration and the work will be performed at ReForm Biologics’
facilities in Woburn, Massachusetts.

“We are excited to initiate this collaboration with Astellas, a global
leader in turning innovative science into value for patients. We
appreciate the efforts of Astellas Innovation Management team in getting
the agreement completed,” said John M. Sorvillo, Ph.D., Chief Executive
Officer, ReForm Biologics. “This collaboration will demonstrate how new
formulation technologies can optimize dosing and support life cycle
management in pharmaceutical drug development programs. We look forward
to working with Astellas to support the development of this
clinical-stage asset.”

About ReForm Biologics

ReForm Biologics has developed a technology platform that transforms the
formulation of biotherapeutics for the ultimate benefit of patients. Our
patented, FDA-friendly technology can extend product life-cycles, enable
alternative dosing, and improve manufacturing efficiency for our
biopharmaceutical partners. With multiple industry alliances to date, we
offer formulation development collaborations and product-specific
licenses for a broad spectrum of protein-based therapeutics.

We don’t make biologics — we make biologics better. www.reformbiologics.com

About Astellas Pharma Inc.

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to
improving the health of people around the world through the provision of
innovative and reliable pharmaceutical products. For more information,
please visit our website at http://www.astellas.com/en

Contacts

Rob Kloppenburg
Shoreline Biotech Communications
(617) 930-5595